The emerging recognition of BAP31 as a promising therapeutic target for cancer is supported by studies demonstrating its promotion of proliferation, invasion, and metastasis in liver cancer cells [13], as well as its ability to induce cell death in gastric cancer through the regulation of p27 proteasome degradation [15]. Here, BCAP31 is linked to liver cancer.